Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 4 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Metastatic HER2 Positive Gastroesophageal Junction Cancer 1 High-risk Non-muscle Invasive Bladder Cancer 1 Breast Neoplasms 1

Interventions

Gemcitabine 17 pembrolizumab 16 Cisplatin 14 enfortumab vedotin 7 avelumab 7 Nivolumab 6 Docetaxel 6 atezolizumab 5 Paclitaxel 5 Cystectomy 5 sacituzumab govitecan 4 durvalumab 4 Mitomycin 4 Cystoscopy 4 Carboplatin 4 vofatamab 3 tremelimumab 3 Radiotherapy 3 Magnetic Resonance Spectroscopy 3 vinflunine 2 tisotumab vedotin 2 poly ICLC 2 cemiplimab 2 aldesleukin 2 Transurethral Resection of Bladder 2 Radiotherapy, Intensity-Modulated 2 Ipilimumab 2 Interleukin-2 2 Immunoglobulin G 2 Clinical Trials, Phase II as Topic 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Urinary Bladder Neoplasms × disitamab vedotin × Clear all

NCT06957561 2025-05-04

DIVON

Sun Yat-sen University

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡